- Home
- / Fate Therapeutics
Fate Therapeutics
Stock Price
$2.7
2024-10-29
Market Capitalization
$309.7 M
2024-10-29
Revenue
$6.6 M
FY, 2025
Fate Therapeutics Summary
Company Summary
- Overview
- Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies. The Company's pipeline is comprised of cell-based therapies for cancer and immune disorders. Its cellular immunotherapies are based on ex vivo cell programming approach to modulate the therapeutic function and direct the fate of hematopoietic cells.
- Type
- Public
- Status
- Active
- Founded
- 2007
- HQ
- San Diego, CA, US | view all locations
- Cybersecurity rating
- ESG rating
- Sectors
Table of Contents
Key People
William Rastetter, Chairman
John Mendlein, Vice Chairman
Bob Valamehr, Chief Research and Development Officer
LocationsView all
2 locations detected
San Diego, CA HQ
United States
3535 General Atomics Ct
San Diego, CA
United States
12278 Scripps Summit Dr
Fate Therapeutics Financials
Summary Financials
- Revenue (Q1, 2026)
- $1.3M
- Net income (Q1, 2026)
- ($31.2M)
- Cash (Q1, 2026)
- $39.6M
- EBIT (Q1, 2026)
- ($33.0M)
- Enterprise value
- $347.0M